Mereo BioPharma Investors Alerted to April 6, 2026 Deadline

Got story updates? Submit your updates here. ›

National plaintiffs' law firm Berger Montague PC has announced that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) on behalf of investors who purchased American Depositary Shares (ADS) issued by Mereo during the period from June 5, 2023 through December 26, 2025. The lawsuit alleges that Mereo made overwhelmingly positive statements to investors concerning the ORBIT and COSMIC Phase 3 programs, clinical trials to test setrusumab as a treatment for Osteogenesis Imperfecta, when in fact neither study achieved its primary endpoint of reducing the annualized clinical fracture rate.

Why it matters

This case highlights the importance of transparency and accurate disclosure by publicly traded pharmaceutical companies, especially when it comes to the results of critical drug trials. Investors rely on this information to make informed decisions, and any misleading statements can lead to significant losses when the true results are revealed.

The details

According to the lawsuit, when Mereo disclosed on December 29, 2025 that neither the ORBIT nor COSMIC studies had achieved their primary endpoints, the price of Mereo's ADS dropped more than 87%, from a closing price of $2.31 per share on December 26, 2025 to a close of $0.29 per share on December 29, 2025. Investors who purchased Mereo securities during the Class Period may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class.

• The Class Period is from June 5, 2023 through December 26, 2025.
• Mereo disclosed the failed drug trial results on December 29, 2025.
• The investor deadline to seek lead plaintiff status is April 6, 2026.

What they’re saying

What’s next

The judge in the case will decide on April 6, 2026 whether to allow investors to be appointed as lead plaintiffs in the class action lawsuit against Mereo BioPharma.